Policy Notices

• Special Emphasis Notice (SEN): AHRQ Announces Interest in Research on Improving Organizational Health Literacy to Prevent and Manage Chronic Disease
  (NOT-HS-20-009)
  Agency for Healthcare Research and Quality
  

• Flexibilities Available to AHRQ Recipients and Applicants Directly Impacted by the Novel Coronavirus (COVID-19) Due to Loss of Operations
  (NOT-HS-20-010)
  Agency for Healthcare Research and Quality
  

• Reminder: Changes to Forms and Instructions for Research Training Grant, Fellowship, and Career Development Award Applications for Applications Due on or After May 25, 2020
  (NOT-OD-20-090)
  National Institutes of Health
  Agency for Healthcare Research and Quality
  

General Notices

• RESCINDED - Revised and Corrected Notice on Policy Regarding Minimum Level of Effort for NCI-Funded Awards
  (NOT-CA-20-047)
  National Cancer Institute
  

• Pre-Application Webinar for RFA-CA-20-027 and RFA-CA-20-028, Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R01/R21 Clinical Trial Optional)
  (NOT-CA-20-050)
  National Cancer Institute
  

• Guidance for Cost-Related Flexibilities Available to Support of Competitive Research (SCORE) Award Recipients Affected by COVID-19
  (NOT-GM-20-026)
  National Institute of General Medical Sciences
  

• Notice of NHGRI Interest in Receiving Letters Requesting Permission to Submit Applications to Support the NHGRI Research Training and Career Development Annual Meeting (U13)
  (NOT-HG-20-035)
  National Human Genome Research Institute
  

• NHLBI Announces Availability of Frequently Asked Questions (FAQs) for NOT-HL-20-757, Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)
  (NOT-HL-20-759)
  National Heart, Lung, and Blood Institute
  

• NHLBI Announces Availability of Frequently Asked Questions (FAQs) for RFA-HL-21-009, Sickle Pan-African Research Consortium Collaborative Sites (U01 Clinical Trial Optional)
  (NOT-HL-20-780)
  National Heart, Lung, and Blood Institute
  

• NIH Plans to Migrate eRA Modules and Data to the Cloud April 17-20; All Systems Unavailable During Migration Window
  (NOT-OD-20-096)
  National Institutes of Health
  

• RESCINDED - Notice of Information: Change in NCATS Prior Approval Process for New CTSA Program Pilot Projects that Involve Human Subjects Research
  (NOT-TR-20-019)
  National Center for Advancing Translational Sciences
  

Notice of Changes to Funding Opportunities

• Notice to Extend the Expiration Date for RFA-AG-21-016 "Planning Projects for Clinical Trials on Effects of Sustained Reductions in Caloric Intake and Related Dietary Practices in Younger and Older Persons (U01 Clinical Trial Optional)"
  (NOT-AG-20-023)
  National Institute on Aging
  

• Notice to Extend the Expiration Date for PA-18-502 "Advancing the Science of Geriatric Palliative Care (R01 - Clinical Trial Optional)"
  (NOT-AG-20-024)
  National Institute on Aging
  

• Notice to Extend the Expiration Date for PA-18-503 "Advancing the Science of Geriatric Palliative Care (R21 - Clinical Trial Optional)"
  (NOT-AG-20-025)
  National Institute on Aging
  

• Notice of NIA Participation in PAR-20-157 "Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)"
  (NOT-AG-20-027)
  National Institute on Aging
  

• Notice of Expiration of RFA-CA-19-046 "Participant Engagement and Cancer Genome Sequencing (PE-CGS): Coordinating Center (U24 Clinical Trial Not Allowed)
  (NOT-CA-20-046)
  National Cancer Institute
  

• Notice to Extend the Response Date for NOT-DK-20-015, Request for Information: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Strategic Plan
  (NOT-DK-20-019)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of Early Expiration of "Notice of Special Interest (NOSI) regarding the NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed)"
  (NOT-ES-20-016)
  National Institute of Environmental Health Sciences
  

• Notice of Early Expiration of NOT-ES-20-015, "Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)
  (NOT-ES-20-019)
  National Institute of Environmental Health Sciences
  

• Notice of Change to the Application Due Date and correct Section II Award Information - Award Budget for RFA-FD-20-030 "Exploring the use of Real-World Data to Generate Real-World Evidence in Regulatory Decision-Making (U01 Clinical Trials Optional"
  (NOT-FD-20-025)
  Food and Drug Administration
  

• Notice of An Additional Cycle of Receipt Dates Added to PAR-18-307 Developing Interventions for Health-Enhancing Physical Activity (R21/R33 - Clinical Trial Optional)
  (NOT-OD-20-093)
  Office of Disease Prevention
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Drug Abuse
  

• Notice of An Additional Cycle of Receipt Dates Added to PAR-18-324 Testing Interventions for Health-Enhancing Physical Activity (R01 - Clinical Trial Optional)
  (NOT-OD-20-094)
  Office of Disease Prevention
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Minority Health and Health Disparities
  

• Notice of NCATS' Participation in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"
  (NOT-TR-20-013)
  National Center for Advancing Translational Sciences
  

• Notice of NCATS Withdrawal from Participation in PAR-18-691, "Innovative Therapies and Tools for Screenable Disorders in Newborns (R21 Clinical Trial Optional)
  (NOT-TR-20-020)
  National Center for Advancing Translational Sciences
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for Alcohol-HIV/AIDS Program Project Comorbidities, Coinfections, and Complications Research: Intervention and Cross-Cutting Foundational Research (P01 Clinical Trial Optional)
  (NOT-AA-20-005)
  National Institute on Alcohol Abuse and Alcoholism
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Collaborative Partnership between on Alcohol Research Centers and Institutions serving Underserved Communities and Populations (U54 Clinical Trial Optional)
  (NOT-AA-20-006)
  National Institute on Alcohol Abuse and Alcoholism
  

Requests for Proposal

• Pre-Solicitation Notice: Preclinical and Translational Vaccine Development for HIV and Other Candidate Agents, RFP: 75N93019R00023
  (NOT-AI-20-041)
  National Institute of Allergy and Infectious Diseases
  

• Pre-Solicitation Notice: Immunology Quality Assessment (IQA) Program, RFP: 75N93020R00007
  (NOT-AI-20-042)
  National Institute of Allergy and Infectious Diseases
  

Notices of Special Interest

• Notice of Special Interest (NOSI): Availability of Administrative Supplements and Urgent Competitive Revisions for Research on Stress Management in Relation to Coronavirus Disease 2019 (COVID-19)
  (NOT-AT-20-011)
  National Center for Complementary and Integrative Health
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  Office of Disease Prevention
  

• Notice of Special Interest (NOSI): National Cancer Institute Announcement Regarding Availability of Urgent Competitive Revision and Administrative Supplements on Coronavirus Disease 2019 (COVID-19)
  (NOT-CA-20-042)
  National Cancer Institute
  

• Notice of Special Interest (NOSI): National Cancer Institute Announcement regarding Availability of Competitive Revision SBIR/STTR Supplements on Coronavirus Disease 2019 (COVID-19)
  (NOT-CA-20-043)
  National Cancer Institute
  

• Notice of Special Interest (NOSI): Single-Cell Proteomics for Interrogating Premalignant and Early Malignant Lesions
  (NOT-CA-20-044)
  National Cancer Institute
  

• Notice of Special Interest (NOSI): Advancing Cancer Data Repositories and Knowledgebases
  (NOT-CA-20-045)
  National Cancer Institute
  

• Notice of Special Interest (NOSI): Neuroimmune Signaling and Function in Substance Use Disorders
  (NOT-DA-20-046)
  National Institute on Drug Abuse
  

• Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19)
  (NOT-DC-20-004)
  National Institute on Deafness and Other Communication Disorders
  

• Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK
  (NOT-DK-20-018)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) Related to HIV Comorbidities, Coinfections, and Complications within NIDDK's Mission
  (NOT-DK-20-020)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of Special Interest (NOSI): Small Business Research and Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)
  (NOT-EB-20-006)
  National Institute of Biomedical Imaging and Bioengineering
  

• Notice of Special Interest (NOSI): Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)
  (NOT-EB-20-007)
  National Institute of Biomedical Imaging and Bioengineering
  

• Notice of Special Interest (NOSI): Availability of Emergency Competitive Revision and Administrative Supplements on Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)
  (NOT-EB-20-008)
  National Institute of Biomedical Imaging and Bioengineering
  

• Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)
  (NOT-ES-20-015)
  National Institute of Environmental Health Sciences
  

• NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed)
  (NOT-ES-20-017)
  National Institute of Environmental Health Sciences
  

• Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)
  (NOT-ES-20-020)
  National Institute of Environmental Health Sciences
  

• Notice of Special Interest (NOSI): Urgent Competitive Revisions to Accelerate Research on the Development of Predictive Models of the Spread of SARS-CoV-2 and Outcomes of Potential Public Health Interventions on COVID-19
  (NOT-GM-20-027)
  National Institute of General Medical Sciences
  

• Notice of Special Interest: Ancillary Reproductive Health Projects to Existing Large and/or Longitudinal Studies
  (NOT-HD-20-008)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Cancer Institute
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute on Minority Health and Health Disparities
  Office of Behavioral and Social Sciences Research
  Office of Research on Women's Health
  

• Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities
  (NOT-MD-20-019)
  National Institute on Minority Health and Health Disparities
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Mental Health
  Office of Disease Prevention
  

• Notice of Special Interest (NOSI): Supporting Research Education in High-Priority Intervention and Services Research Areas for Mentoring Networks for Mental Health Research Education and Short Courses for Mental Health Related Research
  (NOT-MH-20-041)
  National Institute of Mental Health
  

• Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus
  (NOT-MH-20-047)
  National Institute of Mental Health
  National Institute on Alcohol Abuse and Alcoholism
  Office of Disease Prevention
  

• Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for Administrative Supplements to Promote Training in Clinical Research on Pain (Admin Supp Clinical Trial Not Allowed)
  (NOT-NS-20-044)
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of Special Interestregarding the Availability of Administrative Supplements and Urgent Competitive Revisions for the Establishment and Maintenance of a Research Database for Neurological Manifestations of the SARS-CoV-2
  (NOT-NS-20-046)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Special Interest: Clinical and Translational Science Award (CTSA) Program Administrative Supplements
  (NOT-TR-20-014)
  National Center for Advancing Translational Sciences
  

• Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus
  (NOT-TR-20-016)
  National Center for Advancing Translational Sciences
  

• Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus
  (NOT-TR-20-017)
  National Center for Advancing Translational Sciences
  

Funding Opportunities

• Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD) Exploratory/Developmental Research Projects (UH2 Clinical Trial Optional)
  (RFA-AA-20-008)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): May 19, 2020
  
  

• Limited Competition: International Epidemiology Databases to Evaluate AIDS (IeDEA) (U01 Clinical Trial Not Allowed)
  (RFA-AI-20-023)
  National Institute of Allergy and Infectious Diseases
  John E. Fogarty International Center
  National Cancer Institute
  National Heart, Lung, and Blood Institute
  National Institute on Alcohol Abuse and Alcoholism
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Mental Health
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
  
  

• Limited Competition: National Biocontainment Laboratories (NBLs) Operations Support (UC7 Clinical Trial Not Allowed)
  (RFA-AI-20-026)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): July 17, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• NIAMS Rheumatic Diseases Research Resource-based Centers (P30- Clinical Trial Not Allowed)
  (RFA-AR-21-002)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Application Receipt Date(s): October 6, 2020, by 5:00 PM local time of applicant organization. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply corrections to errors found in the application during the submission process by the due date.
  
  

• Utilizing Cohort Studies to Address Health Outcomes in Cancer Survivors (UG3/UH3 Clinical Trial Not Allowed)
  (RFA-CA-20-030)
  National Cancer Institute
  Application Receipt Date(s): July 7, 2020
  
  

• Reducing Stigma Related to Drug Use in Human Service Settings (R34 Clinical Trial Required)
  (RFA-DA-21-001)
  National Institute on Drug Abuse
  National Institute of Mental Health
  Application Receipt Date(s): Only Accepting applications for the AIDS Application Due Date listed below
  
  

• Reducing Stigma Related to Drug Use in Human Service Settings (R21 Clinical Trial Optional)
  (RFA-DA-21-002)
  National Institute on Drug Abuse
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date listed below
  
  

• CBER FY20 FOA for AAV vector manufacturing for diseases affecting very small populations (R01) Clinical Trial Not Allowed
  (RFA-FD-20-032)
  Food and Drug Administration
  Application Receipt Date(s): June 23, 2020 by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
  
  

• Development of Fertility Regulation Methods by Small Business (R43/R44 Clinical Trial Optional)
  (RFA-HD-21-007)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): July 30, 2020
  
  

• Addressing Racial Disparities in Maternal Mortality and Morbidity (R01 Clinical Trial Optional)
  (RFA-MD-20-008)
  National Institute on Minority Health and Health Disparities
  National Heart, Lung, and Blood Institute
  National Institute of Nursing Research
  Office of the Director, NIH
  Application Receipt Date(s): May 29, 2020 No late applications will be accepted for this Funding Opportunity Announcement.
  
  

• NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional)
  (RFA-MH-20-525)
  National Institute of Mental Health
  Application Receipt Date(s): June 20, 2020; June 20, 2021; June 20, 2022 No late applications will be accepted for this Funding Opportunity Announcement